{"id":"NCT03847896","sponsor":"Bond Avillion 2 Development LP","briefTitle":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma","officialTitle":"A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-20","primaryCompletion":"2021-07-20","completion":"2021-07-20","firstPosted":"2019-02-20","resultsPosted":"2022-09-30","lastUpdate":"2023-04-13"},"enrollment":1001,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)","otherNames":[]},{"type":"DRUG","name":"Budesonide metered dose inhaler / BD MDI 160 µg","otherNames":[]},{"type":"DRUG","name":"Albuterol sulfate metered dose inhaler / AS MDI 180 μg","otherNames":[]},{"type":"OTHER","name":"Placebo metered-dose inhaler / Placebo MDI","otherNames":[]}],"arms":[{"label":"BDA MDI (PT027) 160/180 μg","type":"EXPERIMENTAL"},{"label":"BDA MDI (PT027) 80/180 μg","type":"EXPERIMENTAL"},{"label":"BD MDI (PT008) 160 µg","type":"ACTIVE_COMPARATOR"},{"label":"AS MDI (PT007) 180 µg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of budesonide/albuterol BDA MDI (PT027) to its components budesonide BD MDI (PT008) and albuterol AS MDI (PT007) on improvement in lung function and asthma symptoms after 12 weeks of treatment in adult, adolescent, and child subjects with symptomatic asthma currently being treated with a short/rapid-acting β2-adrenoreceptor agonist (SABA) as needed alone or with low-dose inhaled corticosteroid (ICS) maintenance therapy plus SABA as needed.","primaryOutcome":{"measure":"Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Concentration Curve From 0 to 6 Hours (AUC0-6 Hours) Over 12 Weeks","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"BDA MDI (PT027) 160/180 μg","deltaMin":258.6,"sd":18.87},{"arm":"BDA MDI (PT027) 80/180 μg","deltaMin":242.2,"sd":18.8},{"arm":"BD MDI (PT008) 160 µg","deltaMin":178,"sd":18.79},{"arm":"AS MDI (PT007) 180 µg","deltaMin":157.2,"sd":19.08},{"arm":"Placebo MDI","deltaMin":96.7,"sd":19.02}],"pValues":[{"comp":"OG003 vs OG004","p":"0.025"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.003"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":129,"countries":["United States","Argentina","Czechia","Germany","Serbia","Slovakia","Ukraine"]},"refs":{"pmids":["37003355"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":197},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Nausea","Upper respiratory tract infection"]}}